Relapse in Guillain-Barré syndrome after treatment with human immune globulin

Neurology. 1993 May;43(5):872-5. doi: 10.1212/wnl.43.5.872.


Seven adult patients received human immune globulin intravenously as initial therapy for Guillain-Barré syndrome. Although all patients initially stabilized or improved, five patients deteriorated 1 to 16 days after completion of treatment. In all five patients, clinical worsening included loss of at least one functional grade together with a decreased forced vital capacity. We subsequently treated each patient with a course of plasma exchange, which led to varying degrees of clinical improvement in four. In contrast to previously reported relapse rates for Guillain-Barré syndrome, our experience suggests that clinically significant relapses may occur in patients more often following human immune globulin therapy than after either plasma exchange or no therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Female
  • Humans
  • Immunization, Passive*
  • Immunoglobulins / administration & dosage*
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Polyradiculoneuropathy / immunology
  • Polyradiculoneuropathy / physiopathology
  • Polyradiculoneuropathy / therapy*
  • Recurrence
  • Treatment Outcome


  • Immunoglobulins